Ibudilast, a Phosphodiesterase Inhibitor, in Combination with Low-dose Aspirin Potently Inhibits Guinea Pig Carotid Artery Thrombosis without Extending Bleeding Time and Causing Gastric Mucosal Injury

Abstract

A combination of low-dose aspirin (ASA) and a phosphodiesterase inhibitor has been clinically tried for the secondary prevention of atherothrombotic diseases. The in vivo antithrombotic property of ibudilast (CAS 50847-11-5), a phosphodiesterase 4 (PDE4) inhibitor, was evaluated in a photochemically-induced guinea pig carotid artery thrombosis model in combination with low-dose ASA. The time required to decrease the carotid artery blood flow to the reading “zero” was defined as the time to occlusion (TTO) of the artery through thrombogenesis. Each independent use of ASA (300 mg/kg, p.o.) and ibudilast (3 and 10 mg/kg, p.o.) significantly prolonged the TTO, and ASA (300 mg/kg) significantly increased bleeding time (BT) and gastric mucosal injury. A selective PDE4 inhibitor rolipram (1 and 5 mg/kg, p.o.) tended to prolong the TTO without extending BT. ASA (100 mg/kg) plus ibudilast (3 mg/kg) and ASA (100 mg/kg) plus rolipram (5 mg/kg) markedly prolonged the TTO compared with each agent alone. Interestingly, ASA (100 mg/kg) plus ibudilast (3 mg/kg) caused a longer TTO than ASA (300 mg/kg) alone, without significant extension of BT and gastric mucosal injury as observed in ASA (300 mg/kg). These results indicate that the combination of low-dose ASA and ibudilast has a more potent antithrombotic effect than ASA alone without increasing bleeding tendency and gastric mucosal injury. The potent in vivo antithrombotic effect of this combination may be brought about by an action that is associated with PDE4 inhibition of ibudilast.

Key words

ibudilast - CAS 50847-11-5 - antithrombotic effect - phosphodiesterase 4 inhibitor - aspirin

• References

• 1 Lloyd-Jones D, Adams RJ, Brown TM et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121: 948-954
• 2 Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-1218
• 3 Antithrombotic Trialists’ (ATT) Collaboration . Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860
• 4 Shiotani A, Kamada T, Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol 2008; 43: 581-588
• 5 Nema H, Kato M. Investigation of gastroduodenal mucosal injuries caused by low-dose aspirin therapy in patients with cerebral infarction. J Gastroenterol Hepatol 2010; 25: S119-S121
• 6 Nishida U, Kato M, Nishida M et al. Evaluation of gastrointestinal injury and blood flow of small bowel during low-dose aspirin administration. J Clin Biochem Nutr 2011; 48: 245-250
• 7 Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost 2011; 9: 92-104
• 8 Shinohara Y, Katayama Y, Uchiyama S et al., CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959-968
• 9 Uchiyama S, Ikeda Y, Urano Y et al. The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. Cerebrovasc Dis 2011; 31: 601-613
• 10 Theoret JF, Bienvenu JG, Kumar A et al. P-selectin antagonism with recombinant P-selectin glycoprotein ligand-1 (rPSGL-1) inhibits circulating activated platelet binding to neutrophils induced by damaged arterial surfaces. J Pharmacol Exp Ther 2001; 298: 658-664
• 11 Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300: 729-735
• 12 Grau AJ, Sigmund R, Hacke W. Modification of platelet aggregation by leukocytes in acute ischemic stroke. Stroke 1994; 25: 2149-2152
• 13 Prescott SM, McIntyre TM, Zimmerman GA et al. Sol Sherry lecture in thrombosis: molecular events in acute inflammation. Arterioscler Thromb Vasc Biol 2002; 22: 727-733
• 14 Gleissner CA, von Hundelshausen P, Ley K. Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol 2008; 28: 1920-1927
• 15 Sanz MJ, Alvarez A, Piqueras L et al. Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation. Br J Pharmacol 2002; 135: 1872-1881
• 16 Kishi Y, Ohta S, Kasuya N et al. Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovasc Drug Rev 2001; 19: 215-225
• 17 Izumi Y, Gotoh F, Fukuuchi Y et al. Effects of 3-isobutyryl-2-isopropylpyrazolo1,5-apyridine on cerebral circulation and metabolism in cats. Arzneimittelforschung 1990; 40: 1300-1303
• 18 Yamazaki T, Anraku T, Matsuzawa S. Ibudilast, a mixed PDE3/4 inhibitor, causes a selective and nitric oxide/cGMP-independent relaxation of the intracranial vertebrobasilar artery. Eur J Pharmacol 2011; 650: 605-611
• 19 Inoue N, Harada M. Effect of ibudilast on non-specific symptoms in patients with chronic cerebral ischemia. Analysis of cerebral blood flow. Arzneimittelforschung 2008; 58: 277-282
• 20 Gibson LC, Hastings SF, McPhee I et al. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol 2006; 538: 39-42
• 21 Rolan P, Hutchinson M, Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother 2009; 10: 2897-2904
• 22 Ledeboer A, Hutchinson MR, Watkins LR et al. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 2007; 16: 935-950
• 23 Cho Y, Crichlow GV, Vermeire JJ et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA 2010; 107: 11313-11318
• 24 Suzumura A, Ito A, Yoshikawa M et al. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res 1999; 837: 203-212
• 25 Matsuno H, Uematsu T, Nagashima S et al. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Methods 1991; 25: 303-317
• 26 Takiguchi Y, Hirata Y, Wada K et al. Arterial thrombosis model with photochemical reaction in guinea-pig and its property. Thromb Res 1992; 67: 435-445
• 27 Kawamura M, Tsuji N, Moriya N et al. Effects of TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys. Thromb Res 1997; 86: 275-285
• 28 Kogushi M, Matsuoka T, Kawata T et al. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur J Pharmacol 2011; 657: 131-137
• 29 Zhou W, Javors MA, Olson MS. Platelet-activating factor as an intercellular signal in neutrophil-dependent platelet activation. J Immunol 1992; 149: 1763-1769
• 30 Bornstein NM. Antiplatelet drugs: how to select them and possibilities of combined treatment. Cerebrovasc Dis 2001; 11: 96-99
• 31 Benedek IH, Joshi AS, Pieniaszek HJ et al. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 1995; 35: 1181-1186
• 32 Zimmerman GA, McIntyre TM, Prescott SM. Adhesion and signaling in vascular cell–cell interactions. J Clin Invest 1996; 15 98: 1699-1702
• 33 Rickards KJ, Andrews MJ, Waterworth TH et al. Differential effects of phosphodiesterase inhibitors on platelet activating factor (PAF)- and adenosine diphosphate (ADP)-induced equine platelet aggregation. J Vet Pharmacol Ther 2003; 26: 277-282
• 34 Wright CD, Kuipers PJ, Kobylarz-Singer D et al. Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem Pharmacol 1990; 40: 699-707
• 35 Niwa M, Kohno K, al-Essa LY et al. Ibudilast, an anti-allergic and cerebral vasodilator, modulates superoxide production in human neutrophils. Life Sci 1995; 56: 107-115
• 36 Rile G, Yatomi Y, Qi R et al. Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells. Thromb Res 2001; 102: 239-246
• 37 Ohashi M, Kito J, Nishino K. Mode of cerebral vasodilating action of KC-404 in isolated canine basilar artery. Arch Int Pharmacodyn Ther 1986; 280: 216-229
• 38 Siebert DJ, Bochner F, Imhoff DM et al. Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther 1983; 33: 367-374
• 39 Rolan P, Gibbons JA, He L et al. Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. Br J Clin Pharmacol 2008; 66: 792-801